Verona Pharma Plc ADR (NASDAQ: VRNA) open the trading on Thursday, with great promise as it jumped 3.79% to $48.20, before settling in for the price of $46.44 at the close. Taking a more long-term approach, VRNA posted a 52-week range of $11.39-$47.29.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -49.71%. Meanwhile, its Annual Earning per share during the time was 19.36%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -200.00%. This publicly-traded company’s shares outstanding now amounts to $81.83 million, simultaneously with a float of $68.91 million. The organization now has a market capitalization sitting at $3.94 billion. At the time of writing, stock’s 50-day Moving Average stood at $39.28, while the 200-day Moving Average is $25.37.
Verona Pharma Plc ADR (VRNA) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Verona Pharma Plc ADR’s current insider ownership accounts for 15.79%, in contrast to 67.31% institutional ownership. According to the most recent insider trade that took place on Dec 05 ’24, this organization’s President and CEO sold 640,264 shares at the rate of 5.01, making the entire transaction reach 3,205,226 in total value, affecting insider ownership by 14,367,552. Preceding that transaction, on Dec 06 ’24, Company’s President and CEO sold 162,800 for 5.01, making the whole transaction’s value amount to 815,400. This particular insider is now the holder of 14,204,752 in total.
Verona Pharma Plc ADR (VRNA) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.11 per share during the current fiscal year.
Verona Pharma Plc ADR’s EPS decrease for this current 12-month fiscal period is -200.00% and is forecasted to reach -0.12 in the upcoming year.
Verona Pharma Plc ADR (NASDAQ: VRNA) Trading Performance Indicators
Let’s observe the current performance indicators for Verona Pharma Plc ADR (VRNA). It’s Quick Ratio in the last reported quarter now stands at 13.03. The Stock has managed to achieve an average true range (ATR) of 1.98. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 694.40.
In the same vein, VRNA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.94, a figure that is expected to reach -0.05 in the next quarter, and analysts are predicting that it will be -0.12 at the market close of one year from today.
Technical Analysis of Verona Pharma Plc ADR (VRNA)
During the previous 9 days, stock’s Stochastic %D was recorded 89.92% While, its Average True Range was 2.10.
Raw Stochastic average of Verona Pharma Plc ADR (VRNA) in the period of the previous 100 days is set at 97.31%, which indicates a major rise in contrast to 93.00% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 49.13% that was higher than 46.71% volatility it exhibited in the past 100-days period.
